Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 0.41 |
| ▸ | CYP2A6 | P11509 | 3/20 | 0.41 |
| ▸ | TP53 | P04637 | 2/20 | 0.39 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.38 |
| ▸ | DRD2 | P14416 | 1/20 | 0.38 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.38 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.38 |
| ▸ | CHRM5 | P08912 | 2/20 | 0.38 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.38 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.38 |
| ▸ | PKM | P14618 | 1/20 | 0.36 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.34 |
| ▸ | KDM1A | O60341 | 1/20 | 0.34 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.33 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.33 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.33 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.33 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.33 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.33 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13957759 | 1.00 | MAPT (0.41) | MAPTCYP2A6TP53SLC6A4DRD2 | |
| SCHEMBL29516775 | 0.72 | MEN1 (0.33) | PKM | |
| SCHEMBL9913795 | 0.72 | MEN1 (0.33) | PKM | |
| SCHEMBL2913969 | 0.72 | MEN1 (0.33) | PKM | |
| SCHEMBL12661273 | 0.72 | MEN1 (0.33) | PKM | |
| SCHEMBL14092707 | 0.72 | MEN1 (0.33) | PKM | |
| SCHEMBL14045335 | 0.72 | MEN1 (0.33) | PKM | |
| SCHEMBL19968395 | 0.72 | MEN1 (0.33) | PKM | |
| SCHEMBL12084063 | 0.72 | MEN1 (0.33) | PKM | |
| SCHEMBL2592750 | 0.72 | MEN1 (0.33) | PKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1483273-B1 | LIGANDS FOR ASYMMETRIC REACTIONS | SOLVIAS AG (CH) | 2009-01-07 | — | — | EP | disclosed |
| US-7407910-B2 | Ligands for asymmetric reactions | SOLVIAS AG (CH) | 2008-08-05 | — | — | US | disclosed |
| US-7407910-B2 | Ligands for asymmetric reactions | SOLVIAS AG (CH) | 2008-08-05 | — | — | US | disclosed |
| US-7407910-B2 | Ligands for asymmetric reactions | SOLVIAS AG (CH) | 2008-08-05 | — | — | US | disclosed |
| US-20060241307-A1 | Bidentate having a heterocyclic ring, especially benzothiophene, 2,3-disubstituted with phosphonate, phosphine, phosphine oxide, dioxyphosphine or diaminophosphine groups; transition metal complexes; hydrogenation, isomerizatioin, hydroformylation, hydroboration, hydrosilylation or hydrocyanation | BERENS ULRICH | 2006-10-26 | — | — | US | disclosed |
| US-7094907-B2 | Ligands for asymmetric reactions | SOLVIAS AG (CH) | 2006-08-22 | — | — | US | disclosed |
| US-20040260091-A1 | Ligands for asymmetric reactions | SOLVIAS AG (CH) | 2004-12-23 | — | — | US | disclosed |
| EP-1483273-A2 | LIGANDS FOR ASYMMETRIC REACTIONS | Solvias AG (CH) | 2004-12-08 | — | — | EP | disclosed |
| WO-2003031456-A2 | LIGANDS FOR ASYMMETRIC REACTIONS | SOLVIAS AG (CH) | 2003-04-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060241307-A1 | Bidentate having a heterocyclic ring, especially benzothiophene, 2,3-disubstituted with phosphonate, phosphine, phosphine oxide, dioxyphosphine or diaminophosphine groups; transition metal complexes; hydrogenation, isomerizatioin, hydroformylation, hydroboration, hydrosilylation or hydrocyanation | NR2E3, WNK2, OXSR1 | MAPT 4013/4885CYP2A6 1546/4885TP53 3943/4885 |
| US-20040260091-A1 | Ligands for asymmetric reactions | COASY, ICMT, AP2M1 | MAPT 4284/4885CYP2A6 399/4885TP53 3675/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.